| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e75c035c039de44304823b8b779640c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6185d22255d9137b051c0085bbe4ce1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96121ebf7adca9a920515d045fcd9b40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2abc6860c74cb39509b3b592b3a143f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94bf4f0b338996c889f8041459e3d30c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_153ae69eed34c3caf715379b30dd185f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2005-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83a111f3246dba8ad771b415d98e6c6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7fc8a652362f0c7075e5d0f3340338a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdb579e10ff9ba140912b900c5513b16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8baa744b3092a239b4bc89d0e5cd6f2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7cfeb2cde48f2b14b34d1deee019e84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0dbd72c4eb6275722ec523d5eea0fdb |
| publicationDate |
2007-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2300104-C2 |
| titleOfInvention |
Method for predicting brain metastatic injuries generalization |
| abstract |
FIELD: medicine. n SUBSTANCE: method involves studying blood plasma chemoluminescence intensity and nitrogen oxide derivatives content. Total percent of changes of said indices relative to reference value is calculated. The change being insignificant like reduction from -21.7% to -148%, single cerebral metastasis is diagnosed. The value growing from 200% to 1000%, multiple metastatic brain injury independent of primary tumor lesion focus localization is diagnosed. n EFFECT: high prognosis accuracy. n 1 tbl |
| priorityDate |
2005-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |